In one such patient (case 423) with an alternate diagnosis of HER2+ breast cancer, they were then able to access standard of care palliative combination therapy with Paclitaxel, Trastuzumab, and Pertuzumab as per PERUSE study.18 While the importance of gene sequencing for this population cannot be understated, techniques such as histomorphology and immunohistochemistry remain critical. The gene discussed is ERBB2; the disease is breast cancer.